Celldex Therapeutics, Inc. (CLDX)
In Vitro & In Vivo Diagnostic Substances
Latest Price
$38.06
TTM P/E
--
Normalized P/E
--
Div Yield
--
Book Value
6.85
P/B Ratio
5.55
Institutional Ownership
100.0% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 8.56M | $271.0M | 12.86% | +480.9K | 2026-03-31 |
| Kynam Capital Management, LP | 5.84M | $185.0M | 8.77% | -102.6K | 2026-03-31 |
| BlackRock, Inc. | 5.37M | $170.0M | 8.07% | -81.9K | 2026-03-31 |
| FMR LLC | 3.75M | $118.0M | 5.63% | -1.16M | 2026-03-31 |
| Point72 Asset Management, L.P. | 3.23M | $102.0M | 4.85% | +1.47M | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.96M | $93.0M | 4.45% | -- | 2026-03-31 |
| STATE STREET CORP | 2.80M | $88.0M | 4.21% | -593.5K | 2026-03-31 |
| Commodore Capital LP | 2.70M | $85.0M | 4.05% | +131.6K | 2026-03-31 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.09M | $66.0M | 3.13% | +46.6K | 2026-03-31 |
| Eversept Partners, LP | 1.79M | $56.0M | 2.69% | +353.3K | 2026-03-31 |